Scarica l'app Stockscreener
94.89
0.01%
0.01
Dopo l'orario di chiusura:
95.01
0.12
+0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRUS Giù?
Forum
Previsione
Merus N V Borsa (MRUS) Ultime notizie
Merus NV stock hits all-time high at $95.02 - Investing.com
Merus NV stock hits all-time high at $95.02 By Investing.com - Investing.com Australia
Understanding Merus N.V.’s price movementWeekly Profit Summary & Risk Managed Investment Entry Signals - newser.com
Can you recover from losses in Merus N.V.2025 Winners & Losers & Real-Time Buy Signal Alerts - newser.com
Will Merus N.V. (2GH) stock maintain strong growthGold Moves & Fast Entry Momentum Trade Alerts - newser.com
Will Merus N.V. outperform the marketSwing Trade & Free Weekly Watchlist of Top Performers - newser.com
Will Merus N.V. stock sustain high P E ratiosWeekly Risk Report & Daily Chart Pattern Signals - newser.com
Why Merus N.V. is moving todayRate Hike & Weekly Setup with ROI Potential - newser.com
Will Merus N.V. stock deliver better than expected guidanceTrade Ideas & AI Powered Market Entry Ideas - newser.com
Merus Announces Publication of an Abstract on Petosemtamab - GlobeNewswire
Multi factor analysis applied to Merus N.V.Trade Risk Summary & High Accuracy Trade Alerts - newser.com
Op de AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics kondigt Merus de publicatie aan van het abstract over petosemtamab in gemetastaseerde colorectale kanker - GlobeNewswire Inc.
Merus NV Hits New 52-Week High of $95.02, Up 77.85% - Markets Mojo
Merus NV Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Merus (MRUS) Shares Promising Interim Findings from Phase 2 Canc - GuruFocus
Merus announces initial interim data from phase 2 trial of petosemtamab - TipRanks
Merus reports promising early data for petosemtamab in colorectal cancer - Investing.com
Merus reports promising early data for petosemtamab in colorectal cancer By Investing.com - Investing.com Nigeria
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
36 patients: Merus' petosemtamab shows preliminary antitumor activity and manageable safety in mCRC phase 2 - Stock Titan
Will Merus N.V. stock continue upward momentumWeekly Investment Report & Fast Gain Stock Tips - newser.com
Can Merus N.V. stock double in next 5 yearsQuarterly Market Review & Free High Return Stock Watch Alerts - newser.com
Merus Announces Petosemtamab in Metastatic Colorectal - GlobeNewswire
Merus to present petosemtamab data for colorectal cancer at conference By Investing.com - Investing.com Nigeria
Merus N.V. to Present Two Abstracts on Petosemtamab at AACR-NCI-EORTC Conference in Boston - Quiver Quantitative
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
Phase 2 interim data: Merus' petosemtamab to be presented in plenary at AACR Oct 24; poster on cancer stem cells - Stock Titan
Will Merus N.V. price bounce be sustainable2025 Biggest Moves & Daily Stock Trend Watchlist - newser.com
Deals In Depth: September 2025 - insights.citeline.com
Merus (MRUS): Assessing Valuation After Rapid Share Price Gains - Yahoo Finance
Merus N.V. announces proposed public offering of common shares - MSN
Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments - MSN
Merus (NASDAQ:MRUS) Hits New 12-Month HighHere's Why - MarketBeat
Merus (NASDAQ:MRUS) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
Automated trading signals detected on Merus N.V.July 2025 Outlook & Low Risk High Win Rate Picks - newser.com
Is Merus N.V. (2GH) stock safe for risk averse investorsWall Street Watch & Accurate Entry/Exit Alerts - newser.com
What margin trends mean for Merus N.V. stockNew Guidance & Daily Price Action Insights - newser.com
Is Merus NV a good long term investmentTrading Psychology Tips & Market Monitoring and Alerts - earlytimes.in
Merus NV stock hits all-time high at 94.56 USD By Investing.com - Investing.com Nigeria
Merus NV stock hits all-time high at 94.56 USD - Investing.com
Will Merus N.V. stock see PE expansion2025 Short Interest & Real-Time Volume Spike Alerts - newser.com
Why Merus N.V. (2GH) stock could outperform next yearJuly 2025 Movers & Reliable Entry Point Alerts - newser.com
Merus’s SWOT analysis: oncology biotech stock faces acquisition, pipeline promise - Investing.com Nigeria
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):